Effective second line chemotherapy of advanced breast cancer with navelbine and mitomycin C

1993 ◽  
Vol 26 (1) ◽  
pp. 49-53 ◽  
Author(s):  
W. Scheithauer ◽  
G. Kornek ◽  
K. Haider ◽  
W. Kwasny ◽  
T. Schenk ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Mitomycin C ◽  
Advanced Breast ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy

Adriamycin, vinblastine and mitomycin C as second-line chemotherapy in advanced breast cancer

1986 ◽  
Vol 18 (2) ◽  
Author(s):  
Aaron Sulkes ◽  
Eliahu Gez ◽  
M.Raphael Pfeffer ◽  
Raphael Catane ◽  
Rut Isacson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Mitomycin C ◽  
Advanced Breast ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy

Assessment of quality of life during second line chemotherapy for advanced breast cancer

1993 ◽  
Vol 29 ◽  
pp. S85
Author(s):  
E.E. Voest ◽  
P.H.Th. Slee ◽  
H. de Hses ◽  
S.G.L. van der Vegt ◽  
J.W.R. Nortier
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy

scholarly journals Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancer

1995 ◽  
Vol 34 (2) ◽  
pp. 185-189 ◽  
Author(s):  
M. Bontenbal ◽  
A. S. Th. Planting ◽  
J. Verweij ◽  
R. de Wit ◽  
W. H. J. Kruit ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Low Dose ◽  
Advanced Breast ◽  
Oral Etoposide ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Dose Oral ◽  
Line Chemotherapy

Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer

1991 ◽  
Vol 27 (6) ◽  
pp. 477-480 ◽  
Author(s):  
Hellmut Samonigg ◽  
Herbert St�ger ◽  
Anne-Katrin Kasparek ◽  
Marianne Schmid ◽  
Johann Dusleag ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy

scholarly journals The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancer

2019 ◽  
Vol 179 (3) ◽  
pp. 677-685
Author(s):  
Anouk K. M. Claessens ◽  
◽  
Reinier Timman ◽  
Jan J. Busschbach ◽  
Jeanette M. Bouma ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Primary Objective ◽  
Advanced Breast ◽  
Continuous Treatment ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Small Decline ◽  
Line Chemotherapy

Abstract Background The Stop&Go study randomized patients with advanced breast cancer to intermittent (two times four) or continuous (eight subsequent cycles) first- and second-line chemotherapy. Methods QoL was measured with RAND-36 questionnaires every 12 weeks. The primary objective was to estimate differences in changes from baseline between intermittent and continuous treatment. An effect size of 0.5 SD (5 points) was considered clinically meaningful. Results A total of 398 patients were included with a median follow-up of 11.4 months (IQR 5.6–22.2). Mean physical QoL baseline scores were 38.0 resp. 38.2, and mental scores 45.0 resp. 42.4 for intermittent and continuous treatment. Physical QoL declined linearly in the intermittent arm causing a clinically meaningful difference of 5.40 points at 24 months (p < 0.001), while scores in the continuous arm stabilized after a small decline of ± 3.4 points at 12 months. Conversely, mental QoL was fairly stable and even improved with 1.58 (p = 0.005) and 2.48 points (p < 0.001) at 12 months for intermittent and continuous treatment, respectively. When comparing arms for both components in changes from baseline, the maximum differences were 2.46 (p = 0.101) and 1.95 points (p = 0.182) for physical and mental scores, both measured at 30 months and in favor of continuous treatment. Conclusion Intermittent first- and second-line chemotherapy in patients with HER2-negative advanced breast cancer showed a trend for worse impact on QoL compared to continuous chemotherapy, with neither significant nor meaningful differences in course. We recommend prescribing chemotherapy continuously until progressive disease or unacceptable toxicity. Trial registration EudraCT 2010-021519-18; BOOG 2010-02

scholarly journals Weekly low-dose mitoxantrone plus doxorubicin as second-line chemotherapy for advanced breast cancer

1992 ◽  
Vol 21 (2) ◽  
pp. 133-138 ◽  
Author(s):  
M. Bontenbal ◽  
A. S. Th. Planting ◽  
C. J. Rodenburg ◽  
A. Dees ◽  
J. Verweij ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Low Dose ◽  
Advanced Breast ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy

Ifosfamide, Mesna and Epirubicin as Second-Line Chemotherapy in Advanced Breast Cancer

1996 ◽  
Vol 8 (4) ◽  
pp. 310-314 ◽  
Author(s):  
S. Kıraz ◽  
E. Baltali ◽  
N. GüLer ◽  
İ. Barista ◽  
M. Beneklyı ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy

A phase II trial of mitomycin C and 5-fluorouracil as second-line therapy in advanced breast cancer

1990 ◽  
Vol 27 (1) ◽  
pp. 79-80
Author(s):  
Mary E R O'Brien ◽  
E J Bayliss ◽  
Moira E Stewart ◽  
John F Smyth ◽  
Alan Rodger ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Mitomycin C ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Advanced Breast ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy

Treatment of Advanced Breast Cancer with Vinorelbine and Docetaxel With or Without Human Granulocyte Colony-Stimulating Factor

2001 ◽  
Vol 19 (3) ◽  
pp. 621-627 ◽  
Author(s):  
Gabriela V. Kornek ◽  
Herbert Ulrich-Pur ◽  
Melitta Penz ◽  
Karin Haider ◽  
Werner Kwasny ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
Second Line ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
First Line ◽  
Grade 3 ◽  
Stimulating Factor ◽  
Line Chemotherapy

PURPOSE: A multicenter phase II trial was performed to investigate the efficacy and tolerance of docetaxel, vinorelbine with or without recombinant human granulocyte colony-stimulating factor (G-CSF) in patients with metastatic breast cancer. PATIENTS AND METHODS: Between February 1998 and March 1999, 57 patients participated in this trial. Forty-two patients received this combination as first-line and 15 patients as second-line chemotherapy, including 10 patients who had failed anthracyclines. Therapy consisted of vinorelbine 30 mg/m2 on days 1 and 15 and docetaxel 30 mg/m2 on days 1, 8, and 15 every 4 weeks. Depending on the absolute neutrophil counts on the day of scheduled chemotherapeutic drug administration, a 5-day course of G-CSF 5 μg/kg/d was given. RESULTS: The overall response rate was 64.3% (95% confidence interval, 48.1% to 78.4%) in patients receiving docetaxel plus vinorelbine as first-line chemotherapy, including eight complete (19%) and 19 partial remissions (45.3%); 11 patients (26.2%) had disease stabilization, and only four (9.5%) progressed. Second-line treatment with this regimen resulted in eight (53.3%) of 15 objective responses, four had stable disease, and three had progressive disease. The median time to progression was 12 months in the first-line and 9.8 months in the second-line setting, respectively. After a median follow-up time of 18 months, 38 patients (65%) were still alive with metastatic disease. Myelosuppression was commonly observed; World Health Organization grade 3 or 4 neutropenia both occurred in 18 patients (32%) and was complicated by septicemia in four cases; grade 3 or 4 thrombocytopenia was seen in two patients (4%), and grade 3 anemia was seen in only one patient (2%). Severe (grade 3) nonhematologic toxicity, except for alopecia, was rarely observed and included nausea/vomiting in two patients (4%), and stomatitis, peripheral neuropathy, and skin toxicity each in one patient. CONCLUSION: Our data suggest that docetaxel and vinorelbine with or without G-CSF is an effective and fairly well tolerated regimen for the treatment of advanced breast cancer. It might be particularly useful in patients previously exposed to adjuvant or palliative anthracyclines and/or alkylating agents.

Sign in / Sign up

Export Citation Format

Share Document